Health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.
The biology trade is one of 22 market stories StoryVector measures. 92 US ETFs carry it, with $119 billion between them; the largest holder, XLV, holds 36.3% of its capital. This week it ranks 20th of 22 for attention, in the QUIET band. Over the past year its ETFs returned +24.2%, against +16.8% for broad US ETFs, to October 2, 2026; past performance, not a recommendation.
Its level among all 22 on the fixed 25 to 60 scale. The band is where the level sits this week, not a direction.
Its ETFs ranked among the narratives, lowest to highest. The white notch is this one; the thin tick is where broad US ETFs would sit. Measured and past, not a forecast.
What the story is about, where its attention comes from, what sets it off, and what it shares ETFs with.
Health care stocks move on trial results and on what insurers pay. Is this narrative about new science, or about who pays for care?
Genomics, gene editing and new drugs such as the obesity treatments are changing what medicine can do. The value is in what gets discovered and approved.
Most of the capital sits in large drugmakers, insurers, hospitals and device makers. Their results depend on what governments and insurers pay, more than on any single breakthrough.
What would separate them. What moves results. Trial results and approvals fit the first reading. Drug pricing rules, reimbursement and patent expiries fit the second.
Broad health care ETFs hold most of the capital here, and genomics ETFs a small part. We measure the attention and the capital, not the outcome of any trial.
92 ETFs carry this narrative; 84 have it as their main one. Here is how its capital divides among them.
The asset-weighted return of the unlevered ETFs that carry this narrative, against broad US ETFs. Measured and past, not a forecast.
| 1M | 3M | YTD | 1Y | 3Y* | 5Y* | |
|---|---|---|---|---|---|---|
| The biology tradeits ETFs, unlevered | −3.5% | +2.1% | +13.7% | +24.2% | +15.2% | +6.7% |
| rank among the narratives | 17th of 22 | 9th of 22 | 9th of 22 | 3rd of 21 | 15th of 21 | 15th of 21 |
| The marketbroad US ETFs | +0.8% | +2.6% | +14.6% | +16.8% | +22.9% | +12.9% |
1M, 3M, 1Y, 3Y, 5Y: one month to five years. YTD: year to date. * A year, annualized. Rank is among the narratives with a full record for the period. A dash means the narrative’s ETFs do not cover the whole period.
Total return on the market price, each distribution reinvested on its ex-date. The narrative is the asset-weighted return of the unlevered ETFs that carry it; the market is the asset-weighted return of broad US index ETFs. Past performance is no guarantee of future results.
8 categories, each claimed by a written rule. The bar is each one’s share of the capital. The table names what decides each.
| Category | ETFs | Capital | Share of the ETFs | Share of the capital |
|---|---|---|---|---|
| Broad health careWhat governments and insurers pay for drugs and care, and patent expiries at the largest drugmakers | 21 | $77.1 bn | 25% | 65.0% |
| BiotechTrial results and regulatory approvals, and what it costs a company without profits to raise money | 8 | $25.5 bn | 10% | 21.5% |
| PharmaceuticalsDrug pricing rules and patent expiries | 6 | $5.8 bn | 7% | 4.9% |
| Devices and providersHow many procedures are performed and what insurers pay for them, and for insurers, medical costs against premiums | 3 | $4.8 bn | 4% | 4.1% |
| Genomics and health innovationProgress from trial to approved therapy in gene editing and sequencing, and the rate used to value profits years away | 14 | $3.4 bn | 17% | 2.8% |
| Levered and inverse wrappersThe day-to-day path of the biotech and health care indexes, which a daily reset compounds | 20 | $1.4 bn | 24% | 1.2% |
| Everything else | 8 | $0.4 bn | 10% | 0.4% |
| Obesity, aging and longevitySales and trial results for obesity drugs, and spending by and for older people | 4 | $0.2 bn | 5% | 0.1% |
The widest gap: levered and inverse wrappers, 24% of the ETFs and 1.2% of the capital.
What issuers have listed with this as the main narrative, by wrapper.
What issuers have listed, not what anyone expects. A wrapper can be listed before anyone wants it, so a count of ETFs and a share of capital answer different questions.
92 US ETFs carry it. The largest holders of its capital are XLV (36.3%), VHT (15.3%) and IBB (9.4%).
XLV, with 36.3% of the capital in ETFs carrying the story; the top five hold 73.3%.
Its attention level is 41.2 on a scale of 25 to 60, 20th of 22 this week, in the QUIET band. The level averages six channels: search, video, news, forums, investor boards and reference pages.
Asset weighted, its ETFs returned +24.2% over the past year, against +16.8% for broad US ETFs, to October 2, 2026. Past performance only.
Run an ETF in the biology trade? StoryVector shows issuers where their ETFs stand against the closest rivals, every week.
Request a pilot